PI3K activation plays a central role in the development of pulmonary inflammation and tissue remodeling. PI3K inhibitors may thus offer an improved therapeutic opportunity to treat nonresolving lung inflammation but their action is limited by unwanted on-target systemic toxicity. Here we present CL27c, a prodrug pan-PI3K inhibitor designed for local therapy, and investigate whether inhaled CL27c is effective in asthma and pulmonary fibrosis. Mice inhaling CL27c show reduced insulin-evoked Akt phosphorylation in lungs, but no change in other tissues and no increase in blood glycaemia, in line with a local action. In murine models of acute or glucocorticoid-resistant neutrophilic asthma, inhaled CL27c reduces inflammation and improves lung function. Finally, inhaled CL27c administered in a therapeutic setting protects from bleomycin-induced lung fibrosis, ultimately leading to significantly improved survival. Therefore, local delivery of a pan-PI3K inhibitor prodrug reduces systemic on-target side effects but effectively treats asthma and irreversible pulmonary fibrosis.

Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis

Campa, Carlo C.;Margaria, Jean P.;Sala, Valentina;Dal Bello, Federica;Medana, Claudio;TRON, Gian Cesare;Ciraolo, Elisa;Hirsch, Emilio
Last
2018

Abstract

PI3K activation plays a central role in the development of pulmonary inflammation and tissue remodeling. PI3K inhibitors may thus offer an improved therapeutic opportunity to treat nonresolving lung inflammation but their action is limited by unwanted on-target systemic toxicity. Here we present CL27c, a prodrug pan-PI3K inhibitor designed for local therapy, and investigate whether inhaled CL27c is effective in asthma and pulmonary fibrosis. Mice inhaling CL27c show reduced insulin-evoked Akt phosphorylation in lungs, but no change in other tissues and no increase in blood glycaemia, in line with a local action. In murine models of acute or glucocorticoid-resistant neutrophilic asthma, inhaled CL27c reduces inflammation and improves lung function. Finally, inhaled CL27c administered in a therapeutic setting protects from bleomycin-induced lung fibrosis, ultimately leading to significantly improved survival. Therefore, local delivery of a pan-PI3K inhibitor prodrug reduces systemic on-target side effects but effectively treats asthma and irreversible pulmonary fibrosis.
9
1
5232
5247
http://www.nature.com/ncomms/index.html
Administration, Inhalation; Animals; Asthma; Bleomycin; Disease Models, Animal; Enzyme Inhibitors; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Ovalbumin; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Chemistry (all); Biochemistry, Genetics and Molecular Biology (all); Physics and Astronomy (all)
Campa, Carlo C.; Silva, Rangel L.; Margaria, Jean P.; Pirali, Tracey; Mattos, Matheus S.; Kraemer, Lucas R.; Reis, Diego C.; Grosa, Giorgio; Copperi, Francesca; Dalmarco, Eduardo M.; Lima-Júnior, Roberto C. P.; Aprile, Silvio; Sala, Valentina; Dal Bello, Federica; Prado, Douglas Silva; Alves-Filho, Jose Carlos; Medana, Claudio; Cassali, Geovanni D.; Tron, Gian Cesare; Teixeira, Mauro M.; Ciraolo, Elisa; Russo, Remo C.; Hirsch, Emilio
File in questo prodotto:
File Dimensione Formato  
Campa CC et al 2018 Nat Commun.pdf

Accesso aperto

Descrizione: Articolo su rivista
Tipo di file: PDF EDITORIALE
Dimensione 3.09 MB
Formato Adobe PDF
3.09 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1687748
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 51
social impact